Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Prices May Not Be Settled by End of October: President Tajiri of MSNW
August 2, 2010
- Sprycel to Receive FDA Priority Review for Chronic CML in Adults
August 2, 2010
- Prof. Kawabuchi Calls For a Vaccine Law
August 2, 2010
- Asahi Kasei Pharma to Apply for PTH Inj within 2010
August 2, 2010
- FDA Orders GSK to Stop New Patient Enrollment for TIDE Trial
August 2, 2010
- Korosho Underestimates Drug Expenditures: Hodanren
August 2, 2010
- Ranbaxy to Market Levofloxacin in Romania, South Africa
August 2, 2010
- Developed vs Emerging Countries Fail to Agree on Benefit Sharing
August 2, 2010
- MedPeer to Provide “Voices of Doctors”to Drug Companies
August 2, 2010
- 3 FDCs to Gain 50% Share in HIV Drug Market in 2019: Datamonitor
August 2, 2010
- 46.4% of NPhA Members Not Receiving Premium for Generics Dispensing System
August 2, 2010
- Banyu Terminates Copromotion of Singulair with Meiji Seika
August 2, 2010
- Pfizer: Torisel for RCC
August 2, 2010
- Shionogi to Create GDO to Accelerate Global Development
August 2, 2010
- Eli Lilly's Sales in Japan Up 36% in 1st Half of 2010
August 2, 2010
- Bristol-Myers: Orencia for RA
August 2, 2010
- CSTP to Begin Genomic Cohort Study of 100,000 Persons
August 2, 2010
- Chugai to Boost Overseas Sales with Actemra
August 2, 2010
- NBI, Astellas: Micamlo Combination Tablet
August 2, 2010
- All-Japan Strategy Necessary for Genomic Research: Dr Nakamura
August 2, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…